Contineum Therapeutics, Inc. (CTNM)

Market Cap	195.65M
Revenue (ttm)	n/a
Net Income (ttm)	-28.89M
Shares Out	25.78M
EPS (ttm)	-2.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	61,602
Open	8.01
Previous Close	7.90
Day's Range	7.41 - 8.15
52-Week Range	7.04 - 22.00
Beta	n/a
Analysts	Strong Buy
Price Target	29.25 (+285.38%)
Earnings Date	Mar 4, 2025

About CTNM

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 5, 2024
• Employees: 31
• Stock Exchange: NASDAQ
• Ticker Symbol: CTNM
• Website: https://www.contineum-tx.com

Financial Performance

Financial numbers in USD

Analyst Forecast

According to 4 analysts, the average rating for CTNM stock is "Strong Buy." The 12-month stock price forecast is $29.25, which is an increase of 285.38% from the latest price.

Price Target

$29.25

(285.38% upside)

Analyst Consensus: Strong Buy